Issues in the management of HIV-related tuberculosis

Clinics in Chest Medicine

Volumn 26, Issue 2, 2005, Pages 283-294

  Burman, William J ^a,b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b Denver Department of Public Health ^*  (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTACID AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; COTRIMOXAZOLE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; ISONIAZID; KETOCONAZOLE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHADONE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; ZIDOVUDINE; ZINC;

ANEMIA; CHILDHOOD DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; LIVER TOXICITY; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTOPENIA; TUBERCULOSIS; VOMITING;

EID: 17044366172     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2005.02.002     Document Type: Review

References (66)

1. C.R. Horsburgh Jr Priorities for the treatment of latent tuberculosis infection in the United States N Engl J Med 350 20 2004 2060 2067
2. E.L. Corbett, C.J. Watt, and N. Walker The growing burden of tuberculosis: global trends and interactions with the HIV epidemic Arch Intern Med 163 2003 1009 1021
3. W.J. Burman, and B.E. Jones Clinical and radiographic features of HIV-related tuberculosis Semin Respir Infect 18 4 2003 263 271
4. Tuberculosis Trials Consortium Once-weekly rifapentine and isoniazid versus twice-weekly rifampin and isoniazid in the continuation phase of therapy for drug-susceptible pulmonary tuberculosis: a prospective, randomized clinical trial among HIV-negative persons Lancet 360 2002 528 534
5. R.E. Nettles, D. Mazo, and K. Alwood Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use Clin Infect Dis 38 5 2004 731 736
6. C.P. Chaulk, and V.A. Kazandjian Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the Public Health Tuberculosis Guidelines Panel JAMA 279 12 1998 943 948
7. K. Alwood, J. Keruly, and K. Moore-Rice Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients AIDS 8 1994 1103 1108
8. C.R. Driver, S.S. Munsiff, and J. Li Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City Clin Infect Dis 33 10 2001 1762 1769
9. G.R. Davies, C. Connolly, and A.W. Sturm Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa AIDS 13 7 1999 811 817
10. A.N. Ackah, D. Coulibaly, and H. Digbeu Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire Lancet 345 8950 1995 607 610
11. J. Murray, P. Sonnenberg, and S.C. Shearer Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients Am J Respir Crit Care Med 159 3 1999 733 740
12. S. Kassim, M. Sassan-Morokro, and A. Ackah Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa AIDS 9 10 1995 1185 1191
13. C. Connolly, A. Reid, and G. Davies Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa AIDS 13 12 1999 1543 1547
14. R.E. Chaisson, H.C. Clermont, and E.A. Holt Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection Am J Respir Crit Care Med 154 1996 1034 1038
15. R.E. Chaisson, G.F. Schecter, and C.P. Theuer Tuberculosis in patients with acquired immunodeficiency syndrome: clinical features, response to therapy, and survival Am Rev Respir Dis 136 1987 570 574
16. A. Mocroft, S. Vella, and T.L. Benfield Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group Lancet 352 9142 1998 1725 1730
17. P. Garcia de Olalla, M.A. Martinez-Gonzalez, and J.A. Cayla Influence of highly active anti-retroviral therapy (HAART) on the natural history of extra-pulmonary tuberculosis in HIV patients Int J Tuberc Lung Dis 6 12 2002 1051 1057
18. W. Burman, D. Benator, and A. Vernon Use of antiretroviral therapy during treatment of active tuberculosis with a rifabutin-based regimen [abstract 136] Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections 2003 Foundation for Human Retrovirology Boston 106
19. C.C. Hung, M.Y. Chen, and C.F. Hsiao Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy AIDS 17 18 2003 2615 2622
20. J.E. Bennett, W.E. Dismukes, and R.J. Duma A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis N Engl J Med 301 3 1979 126 131
21. S.A. Bozzette, R.A. Larsen, and J. Chiu A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group N Engl J Med 324 9 1991 580 584
22. J.H. Perriens, M.E. St. Louis, and Y.B. Mukadi Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months N Engl J Med 332 1995 779 784
23. P. Sonnenberg, J. Murray, and J.R. Glynn HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers Lancet 358 9294 2001 1687 1693
24. A. van Rie, R. Warren, and M. Richardson Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment N Engl J Med 341 16 1999 1174 1179
25. W. El-Sadr, D.C. Perlman, and J.P. Matts Evaluation of an intensive intermittent-induction regimen and short course duration of treatment for HIV-related pulmonary tuberculosis Clin Infect Dis 26 1998 1148 1158
26. Li J., Munsiff S.S., Driver C.R., et al. Outcome of HIV-infected tuberculosis patients treated with rifabutin or rifampin-based regimens, New York City. 1997-2000 [late-breaker abstract]. Program and abstracts of the International Union Against TB and Lung Disease (IUATLD) World Conference on Lung Health. Paris, October 30-November 2, 2003
27. S.E. Weis, P.C. Slocum, and F.X. Blais The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis N Engl J Med 330 1994 1179 1184
28. W.J. Burman, D.L. Cohn, and C.A. Rietmeijer Noncompliance with directly observed therapy for tuberculosis: epidemiology and effect on the outcome of treatment Chest 111 1997 1168 1173
29. D.A. Mitchison, and A.J. Nunn Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis Am Rev Respir Dis 133 1986 423 430
30. A. Vernon, W. Burman, and D. Benator Relapse with rifamycin mono-resistant tuberculosis in HIV-infected patients treated with supervised once-weekly rifapentine and isoniazid Lancet 353 1999 1843 1847
31. M.H. Skinner, M. Hseih, and J. Torseth Pharmacokinetics of rifabutin Antimicrob Agents Chemother 33 1989 1237 1241
32. M. Weiner, N. Bock, and C.A. Peloquin Pharmacokinetics of rifapentine 600, 900 and 1,200 mg during once-weekly tuberculosis therapy Am J Respir Crit Care Med 169 2004 1191 1197
33. H.M. Blumberg, W.J. Burman, and R.E. Chaisson American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis Am J Respir Crit Care Med 167 4 2003 603 662
34. L.J. Gonzalez-Montaner, S. Natal, and P. Yonchaiyud Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin Tuber Lung Dis 75 1994 341 347
35. S. Schwander, S. Rusch-Gerdes, and A. Mateega A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis: a single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis Tubercle Lung Dis 76 1995 210 218
36. M.M. McGregor, P. Olliaro, and L. Wolmarans Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis Am J Respir Crit Care Med 154 1996 1462 1467
37. D.W. Fitzgerald, M. Desvarieux, and P. Severe Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial Lancet 356 9240 2000 1470 1474
38. G.J. Churchyard, K. Fielding, and S. Charalambous Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS 17 14 2003 2063 2070
39. O. Kirk, J.M. Gatell, and A. Mocroft Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD Am J Respir Crit Care Med 162 3 Pt 1 2000 865 872
40. M. Badri, D. Wilson, and R. Wood Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study Lancet 359 9323 2002 2059 2064
41. P.G. Yeni, S.M. Hammer, and M.S. Hirsch Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel JAMA 292 2 2004 251 265
42. A.M. Elliott, H. Luzze, and M.A. Quigley A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis J Infect Dis 190 5 2004 869 878
43. E. Wood, R.S. Hogg, and B. Yip Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4 + cell count is 0.200 to 0.350 x 10(9) cells/L Ann Intern Med 139 10 2003 810 816
44. J.A. Bartlett, R. DeMasi, and J. Quinn Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults AIDS 15 11 2001 1369 1377
45. N. Singh, S.M. Berman, and S. Swindells Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy Clin Infect Dis 29 4 1999 824 830
46. C. Pradier, L. Bentz, and B. Spire Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study HIV Clin Trials 4 2 2003 121 131
47. B. Jones, M. Otaya, and E. Rayos Directly observed therapy of highly active antiretroviral therapy in patients with HIV and tuberculosis [abstract 60582] Program and abstracts of the 12th World AIDS Conference 1998 Marathon Multimedia Geneva (Switzerland) 1107
48. G.L. Dean, S.G. Edwards, and N.J. Ives Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy AIDS 16 1 2002 75 83
49. S.V. Cook, P.I. Fujiwara, and T.R. Frieden Rates and risk factors for discontinuation of rifampicin Int J Tuberc Lung Dis 4 2 2000 118 122
50. W.J. Burman, K. Gallicano, and C. Peloquin Therapeutic implications of drug interactions in the treatment of HIV-related tuberculosis Clin Infect Dis 28 1999 419 430
51. J. Sahai, K. Gallicano, and L. Oliveras Cations in didanosine tablet reduce ciprofloxacin bioavailability Clin Pharmacol Ther 53 1993 292 297
52. A. Cato, J. Cavanaugh, and H. Shi The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin Clin Pharmacol Ther 63 1998 414 421
53. A. Hsu, G.R. Granneman, and R.J. Bertz Ritonavir. Clinical pharmacokinetics and interactions with other anti- HIV agents Clin Pharmacokinet 35 4 1998 275 291
54. I.H. Benedeck, W.D. Fiske, and S.J. White Pharmacokinetic interaction between multiple doses of efavirenz and rifabutin in healthy volunteers [abstract 461] Program and abstracts of the 36th Annual Meeting of the Infectious Diseases Society of America 1998 Infectious Diseases Society of America Denver (CO)
55. Centers for Disease Control and Prevention TB/HIV Drug Interactions. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase Inhibitors. Updated Jan. 20, 2004 Available at: http://www.cdc.gov/nchstp/tb/TB_HIV_Drugs/TOC.htm Accessed September 6, 2004
56. M.A. French, P. Price, and S.F. Stone Immune restoration disease after antiretroviral therapy AIDS 18 12 2004 1615 1627
57. M. Narita, D. Ashkin, and E.S. Hollender Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS Am J Respir Crit Care Med 158 1998 157 161
58. E. Hollender, M. Narita, and D. Ashkin CNS manifestations of paradoxical reactions in HIV + TB patients on HAART [abstract 258] Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections 2000 Foundation for Human Retrovirology San Francisco (CA) 124
59. J.E. Fishman, E. Saraf-Levi, and M. Narita Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy AJR Am J Roentgenol 174 2000 43 49
60. S.A. Shelburne III, R.J. Hamill, and M.C. Rodriguez-Barradas Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy Medicine (Baltimore) 81 3 2002 213 227
61. R.A. Breen, C.J. Smith, and H. Bettinson Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection Thorax 59 8 2004 704 707
62. J. Olalla, F. Pulido, and R. Rubio Paradoxical responses in a cohort of HIV-1-infected patients with mycobacterial disease Int J Tuberc Lung Dis 6 1 2002 71 75
63. K.A. Wendel, K.S. Alwood, and R. Gachuhi Paradoxical worsening of tuberculosis in HIV-infected persons Chest 120 1 2001 193 197
64. E. Navas, P. Martin-Davila, and L. Moreno Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy Arch Intern Med 162 1 2002 97 99
65. W.J. Burman, and B.E. Jones Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy Am J Respir Crit Care Med 164 1 2001 7 12
66. L. Morris, D.J. Martin, and H. Bredell Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients J Infect Dis 187 12 2003 1967 1971